Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Visiongain Report Offers Transformative Insights on the $33bn Ophthalmic Drugs Market

This image opens in the lightbox

News provided by

Visiongain

22 Aug, 2019, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

Global Ophthalmic Drugs Market Forecast 2019-2029

Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs

LONDON, Aug. 22, 2019 /PRNewswire/ -- The global ophthalmic drugs market is expected to grow at a CAGR of 4.8% in the first half of the forecast period. The market is estimated at $25bn in 2018, dominated by the retinal disorder drugs segment.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 298-page report you will receive 138 tables and 125 figures– all unavailable elsewhere.

The 298-page Visiongain report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-ophthalmic-drugs-market-forecast-2019-2029/#download_sampe_div

Report Scope

• Global Ophthalmic Drugs market forecasts from 2019-2029

• This report also breaks down the revenue forecasts to 2029 for the global ophthalmic drugs market by the leading submarkets:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

• This report includes revenue forecasts to 2029 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas

• This report provides individual revenue forecasts to 2029 for these national markets:
• The US
• Japan
• EU5: Germany, France, the UK, Spain, Italy
• Russia
• China
• India
• Brazil
• Rest of the World

Each national market is further segmented by the leading submarket: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs, Other Ophthalmic Drugs

• Our study provides a SWOT analysis and discusses Porter's Five Forces analysis that influence the global ophthalmic drugs market

• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Allergan (Actavis)
• Bayer
• Novartis
• Pfizer
• Regeneron
• Roche
• Santen
• Senju
• Valeant

• Key Questions Answered by this Analysis:
• How is the market for ophthalmic drugs evolving?
• What is driving and restraining the ophthalmic drugs market dynamics?
• What are the market shares of the submarkets for glaucoma drugs, allergic, inflammatory and infective drugs, dry eye drugs and retinal disorder drugs from the overall ophthalmic Drugs Market in 2018?
• How will each of the submarket segments within the ophthalmic drugs market grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the submarkets within the ophthalmic drugs market develop from 2018 to 2029?
• Which submarkets will be the main driver of growth in the overall market from 2018 to 2029?
• How will political, economic, and regulatory factors influence the regional markets and submarkets?
• Will the leading regional markets for ophthalmic drugs broadly follow pre-existing trends, or will individual regions outperform the rest of the market?
• How will the regional market shares in the ophthalmic drugs market change by 2029 and which geographical region will lead the market in 2029?
• What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry sector evolve as cost and pricing pressures increase during the period between 2018 and 2029?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-ophthalmic-drugs-market-forecast-2019-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

Abbott
AbbVie
Actavis
Acucela
Advanced Cell Technologies
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Inc
Alcon
Alimera Sciences
Allegro
Allergan
Amakem
Amgen
Ampio Pharmaceuticals
Apotex Inc
AstraZeneca
Aurobindo Pharma Ltd
Barr Laboratories Inc.
Bausch & Lomb
Bayer
Bicycle Therapeutics
Biocad
BioDiem
BioXpress Therapeutics
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiesi Farmaceutici S.p.A
Cipla
Colby Pharmaceutical Company
Daiichi Sankyo
Eleven Biotherapeutics
EyeCyte
EyeGate Pharmaceuticals
ForeSight Biotherapeutics
Gene Signal
Genentech
GSK
iCO Therapeutics
Icon Bioscience
InSite Vision
Inspire Pharmaceuticals
Instituto Terapeutico Delta Ltda
Kala Pharmaceuticals
KalVista
Kestrel Ophthalmics
Kyowa Hakko Kirin
LEO Pharma
MacuCLEAR
Meda
Merck & Co.
MerLion Pharmaceuticals
Morgan Stanley
Neurim Pharmaceuticals
Neurotech
NovaBay
Novartis
Ohr Pharmaceutical
Omeros
OphthaliX
Ophthotech Corporation
Oxigene
PanOptica
Patheon Pharmaceuticals
Pfizer
Pharmacia
Premacure
pSivida
QLT
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
Roche
R-Tech UENO
RXi Pharmaceuticals
Santen
SARcodeBioscience
Seikagaku
Senju
Servier
Shire
Sobi
Spark Therapeutics
SymphonyVIDA
Takeda
Thrombogenics
Upjohn
USV North America
Valeant
Vanda Pharmaceuticals
Warner-Lambert
Watson
Wockhardt
Wyeth Pharmaceuticals
Zach System Spa

List of Organizations Mentioned in the Report
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
CDSCO (India)
European Union
European Commission
Health Canada (Canada)
Institute of Experimental Medicine
Italian Competition Authority (ICA)
Italian National Health Service
Japanese Ministry of Health, Labour and Welfare (MHLW)
MCC (South Africa)
MHLW (Japan)
MHRA (UK)
PAHO
SFDA (China)
TGA (Australia)
University of Modena
US National Eye Institute (NEI)
World Health Organization (WHO)
WIPO
WTO

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

The Ophthalmic Equipment Market Forecast 2019-2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Drug Delivery Technologies Market Forecast 2019-2029

Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2019-2029

Biologics Market Trends and Forecasts 2018-2028

Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.